Chiusura precedente | 87,21 |
Aperto | 86,66 |
Denaro | 0,00 x 1300 |
Lettera | 0,00 x 1000 |
Min-Max giorno | 85,53 - 88,51 |
Intervallo di 52 settimane | 72,57 - 169,98 |
Volume | |
Media Volume | 158.288 |
Capitalizzazione | 1,492B |
Beta (5 anni mensile) | 1,22 |
Rapporto PE (ttm) | 67,54 |
EPS (ttm) | 1,31 |
Prossima data utili | 27 lug 2022 - 01 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | 02 lug 2010 |
Stima target 1A | 182,50 |
Key Opinion Leader (KOL) webinar scheduled for Wednesday, June 15, at 10:00 a.m. EDTCOLUMBUS, Ohio, June 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it will host a virtual update on its ELAINE Phase 2 clinical programs on Wednesday, June 15 at 10:00 a.m. EDT. The event will feature presentations from Key
COLUMBUS, Ohio, April 28, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 3-7 at McCormick Place in Chicago and online. Details of the presentations are as follows: Title: Open-lab
Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK inhibitor may limit tumor progression in aromatase inhibitor (AI) resistant tumors not resistant due to an ESR1 mutationCOLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that the company, in collaboratio